Q-omics provides the consensus-scored NPY profile across patient tissues and cancer cell-line models. NPY expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NPY is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, NPY protein abundance shows 21,436 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, COAD, and GBM as cancer lineages where NPY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPY survival associations across molecular data types. NPY RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPY RNA expression–survival associations across cancer types. High NPY expression shows unfavorable associations in UCEC, OV and HNSC, but favorable associations in LUSC, PAAD and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for NPY RNA expression.
This table summarizes NPY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NPY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPY shows lower tumor expression in COAD, STAD, KICH, KIRC, READ and THCA. The COAD box plot shows higher NPY RNA expression in normal versus tumor tissue (log2 FC = −1.702, t-test p < 0.001).
This table shows molecular features associated with NPY in patient tissues and cancer cell lines. In patient samples, NPY shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
